



IDT Awarded Future Industries Manufacturing Program Grant

***... IDT will receive \$265,937 in non-dilutive grant funding from the Victorian Government
...Funds to expand IDT's analytical testing capacity in readiness for US launch of
Temozolomide and other specific IDT portfolio drugs***

6 September 2016, Melbourne: Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) has been awarded \$265,937 from the Victorian Government under its Future Industries Manufacturing Program (FIMP).

Grant funds will be used by IDT to purchase and upgrade laboratory equipment and infrastructure. This will support IDT's analytical testing capabilities in readiness for the US launch of IDT's Temozolomide drug product as well as other priority drugs in the Company's portfolio. IDT will match the FIMP grant funds with a co-contribution of \$3 for every \$1 of grant funding.

The FIMP grant program is an initiative under the Victorian Government's \$200M Future Industries Fund to support high growth industry sectors that are critical to securing Victoria's future as a competitive, innovative and outward looking economy. Medical Technologies and Pharmaceuticals is one of the six key industry sectors under the initiative.

"We are delighted to receive this grant from the Victorian Government, the funds will be immediately put to work building needed analytical capability in anticipation of the US launch of IDT's first wave of generic drug products." said IDT's Managing Director Dr Paul MacLeman, who went on to say: "I would like to take this opportunity to sincerely thank the Victorian Government for their continued support of IDT and for their commitment to the Victorian pharmaceutical and medtech manufacturing industries."

ENDS

For further information please contact:

IDT Australia Limited
Dr Paul MacLeman
Managing Director
(03) 9801 8888

Monsoon Communications
Rudi Michelson
(03) 9620 3333

About IDT

IDT Australia Ltd recently acquired a portfolio of 23 generic drugs to manufacture and sell via US distribution partners. With IDT's 2013 Temozolomide ANDA filing this signifies IDT's move to rapidly become a specialty generics business with near term revenue build up.

IDT (ASX:IDT) is a public Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. It has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are fully cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Through CMAX, its clinical research services business based adjacent to the new Royal Adelaide Hospital in South Australia, IDT also provides full Phase I clinical trials management and delivery, recruitment in specific disease states for Phase II and Phase III trials as well as offering trial packaging, distribution and pharmacy services from the cGMP Boronia facilities.